TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentado sáb, 29 ago · 08:30 CESTHot Line 2Todos los ensayos Hot Line →

AMUNDSEN

2026

Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world

In 2,161 patients with acute myocardial infarction undergoing PCI, evolocumab started before PCI increased achievement of an LDL-C reduction of ≥50 % to below 1.4 mmol/L at 12 months compared with standard lipid-lowering care.

Resultado

Eficacia: Achievement of both a ≥50% LDL-C reduction from baseline and LDL-C <1.4 mmol/L (55 mg/dL) at 12 months; main clinical endpoint the composite of all-cause death or unplanned cardiovascular hospitalisation at 12 monthsadjusted OR 5,54 (IC del 95% 4,50-6,82) · P < 0,001

Por debajo de 1 a favor de standard lipid-lowering care, por encima de 1 a favor de evolocumab started before PCI.

Tasas de eventos
Diferencia absoluta
42,0 puntos
NNT
3

La diferencia absoluta y el NNT se derivan de las tasas de eventos.

También se informa: Primary lipid endpoint met: median LDL-C at 6 weeks 16 vs 56 mg/dL. No clinical benefit: death or unplanned cardiovascular hospitalisation at 12 months 159/1087 (14.6%) vs 165/1074 (15.4%), adjusted OR 0.94 (95% CI 0.73–1.19), p=0.59

Publicación original
Subtema
PCSK9 inhibition in ACS
Diseño
International, investigator-initiated Phase IV PROBE RCT, 1:1, first evolocumab dose given before PCI, 12-month primary follow-up (clinical follow-up continuing to 2028)
Relevancia
Importante: uno de varios pilares.
Fuente
Montalescot G, Ferrari E, Souteyrand G, et al. JAMA. 2026; published online 29 August.doi 10.1001/jama.2026.17302

Discusión y crítica

Giving the PCSK9 antibody before the wire crosses does what the pharmacology promises: four in five reach the guideline target at a year against two in five, with a median LDL-C of 16 mg/dL at six weeks. What it does not do, over twelve months, is change death or cardiovascular readmission: an open-label trial powered for a laboratory endpoint, not for events. The lipid result is the argument for starting early; the clinical arm is the reminder that a year is short for a curve that separates late.

Comentado en pódcasts